PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status | Zendy

Ben Fulton | Zendy; Susan Short | Zendy; Allan James | Zendy; Stefan Nowicki | Zendy; Catherine McBain | Zendy; Sarah Jefferies | Zendy; Caroline Kelly | Zendy; Jon Stobo | Zendy; Anna Morris | Zendy; Aoife Williamson | Zendy; Anthony J. Chalmers | Zendy

Open Access

PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status

Author(s) -

Ben Fulton,

Susan Short,

Allan James,

Stefan Nowicki,

Catherine McBain,

Sarah Jefferies,

Caroline Kelly,

Jon Stobo,

Anna Morris,

Aoife Williamson,

Anthony J. Chalmers

Publication year - 2017

Publication title -

clinical and translational radiation oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.336

H-Index - 15

ISSN - 2405-6308

DOI - 10.1016/j.ctro.2017.11.003

Subject(s) - temozolomide , olaparib , medicine , radiation therapy , glioblastoma , oncology , cancer research , poly adp ribose polymerase , biochemistry , chemistry , polymerase , gene

Glioblastoma has a dismal prognosis and molecular targeted agents have failed to improve outcomes to date. PARADIGM-2 is a phase I dose escalation study evaluating olaparib plus radiotherapy ± temozolomide in newly diagnosed glioblastoma, using MGMT methylation status to stratify patients and inform treatment schedules.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research